ALN-SNCA / Alnylam, Regeneron - LARVOL DELTA

First-in-Human Single-Ascending-Dose Trial of ALN-SNCA, an Intrathecally Administered siRNA for Reducing α-synuclein, in Patients with Early-Stage Parkinson’s Disease (MDS Congress 2026) - No abstract available

Clinical • First-in-human • P1 data • CNS Disorders • Movement Disorders • Parkinson's Disease • SNCA

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Regeneron Pharmaceuticals

First-in-human • Trial initiation date • CNS Disorders • Movement Disorders • Parkinson's Disease

First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) (clinicaltrials.gov) - P1 | N=46 | Recruiting | Sponsor: Regeneron Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • First-in-human • CNS Disorders • Movement Disorders • Parkinson's Disease